NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
ID: 348937Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/348937

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-200.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced the NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed), aimed at accelerating the development of therapeutic interventions for visual system diseases. This funding opportunity supports a phased research approach, where the R61 phase focuses on exploratory activities with preliminary data, while the R33 phase advances preclinical development leading to Investigational New Drug (IND) or Investigational Device Exemption (IDE) submissions. The program is crucial for transforming innovative laboratory findings into clinical therapies that enhance patient care, with a total budget of up to $500,000 annually for R61 and $1,000,000 for R33. Interested applicants must submit their proposals by March 16, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-200-Full-Announcement.html
    PAR-23-200.html
    The National Eye Institute (NEI) of the National Institutes of Health (NIH) has issued a Notice of Funding Opportunity (NOFO) to support the NEI Translational Research Program for Therapeutics, specifically focusing on accelerating the development of therapeutic interventions for visual system diseases. This program allows for a phased research approach (R61/R33) where the R61 phase covers exploratory activities with preliminary data, while the R33 phase supports advanced preclinical development leading to Investigational New Drug (IND) applications or Investigational Device Exemption (IDE) submissions. Applications must involve multidisciplinary teams targeting concrete milestones within a maximum of five years. The total budget for R61 is capped at $500,000 annually, with $1,000,000 for R33. Eligible applicants range from higher education institutions to federal agencies and diverse nonprofit organizations. All applications must adhere to stringent guidelines, including a clear explanation of the project's significance, the expertise of the investigative team, and a defined regulatory strategy. The goal is to produce actionable data that guides an IND/IDE submission, ultimately transforming innovative laboratory findings into clinical therapies that enhance patient care.
    Similar Opportunities
    NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled the NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed) aimed at accelerating the translation of innovative laboratory research into therapeutic interventions for visual system diseases. This program employs a bi-phasic, milestone-driven mechanism consisting of an Exploratory (R61) phase lasting up to two years and a Developmental (R33) phase lasting up to three years, focusing on generating preclinical data that supports applications for Investigational New Drug (IND) or Investigational Device Exemption (IDE) submissions to the FDA. The initiative is designed to engage diverse organizations, including historically black colleges, tribal governments, and community-based organizations, to foster collaborative efforts in ocular research, ultimately improving health outcomes through vision research. Interested applicants can find more information and guidelines at the provided link, with a funding ceiling of $500,000 and a submission deadline of March 16, 2025.
    NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NEI Clinical Research Study Planning Grant Program (R34), aimed at supporting the development of clinical trial protocols and procedures specifically for eye and vision-related studies. This grant facilitates the preparation of a comprehensive Manual of Procedures (MOP) and allows for preliminary studies to assess recruitment potential, without generating data on intervention effects. Grants may provide up to $150,000 per year for a maximum of two years, with applications due by May 7, 2025. Eligible applicants include a wide range of institutions, including educational, nonprofit, and government entities, and inquiries can be directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NEI Regenerative Medicine Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NEI Regenerative Medicine Clinical Trial Planning Grant (R34) to support the development of clinical trial protocols aimed at restoring vision through cell regeneration. This grant is designed to fund essential activities such as creating a Manual of Procedures (MOP), obtaining regulatory approvals, and assessing the feasibility of clinical trials that involve regenerative strategies, particularly those utilizing stem cells. The initiative underscores the federal commitment to advancing vision restoration research, with a funding ceiling of $150,000 per year for projects lasting up to two years. Interested applicants, including various educational institutions and organizations, must adhere to strict submission guidelines via Grants.gov, with applications due by May 7, 2025. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NEI Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Eye Institute (NEI) for cooperative agreements (U01) aimed at supporting early-stage clinical trials that involve greater than minimal risk, specifically targeting interventions for vision disorders. This initiative encourages applications for Phase I or II trials that are backed by strong preliminary data and require compliance with NIH guidelines, including the establishment of a Data Monitoring and Safety Committee (DSMC) for safety oversight. The funding is crucial for advancing research in the screening, diagnosis, prevention, and treatment of vision disorders, with project budgets reflecting actual needs and a maximum project period of five years. Interested applicants can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with the application deadline set for May 7, 2025.
    NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44-Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44), aimed at supporting small business concerns (SBCs) conducting early-stage clinical trials related to vision disorders. Applicants are required to propose studies that evaluate interventions for screening, diagnosing, preventing, or treating eye diseases, with a focus on trials that typically fall under Phase I or II and involve greater than minimal risk, necessitating appropriate oversight and safety monitoring. This initiative underscores the government's commitment to advancing clinical research and innovation in vision health, with applications due by January 7, 2027. Interested applicants can find more information and guidance by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-066.html.
    NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Eye Institute (NEI), is inviting applications for the NEI Research Grant for Vision-Related Secondary Data Analysis (R21), which focuses on funding innovative research projects that utilize existing vision-related datasets for secondary data analyses. This opportunity aims to enhance understanding of vision health issues by encouraging researchers to leverage data from previous clinical trials or epidemiologic studies, while explicitly excluding support for new data collection. Eligible applicants include a wide range of institutions, such as historically black colleges and universities, tribal colleges, and community-based organizations, with a direct cost ceiling of $275,000 for projects lasting up to two years. Interested parties should submit their applications by May 7, 2025, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further information.
    NEI Collaborative Clinical Vision Research Project: Resource Center Grant (UG1 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NEI Collaborative Clinical Vision Research Project, specifically for Resource Center Grants (UG1 Clinical Trial Required). This initiative aims to support large-scale clinical trials focused on screening, diagnosing, preventing, or treating vision disorders, with a particular emphasis on evaluating complex interventions and providing essential services for multi-center trials. The NEI seeks to advance vision health through rigorous research, and applications are encouraged from a diverse range of eligible applicants, including various educational institutions and organizations. Interested parties must submit their applications by May 25, 2026, and can find additional information and guidelines at NIH Grants. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Translational Neural Devices (R61/R33 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Translational Neural Devices (R61/R33 - Clinical Trial Optional)" aimed at advancing the development of therapeutic and diagnostic devices for neurological and neuromuscular disorders. This funding opportunity supports projects through two phases: R61 for non-clinical activities and R33 for small clinical studies, with a focus on ensuring compliance with Environmental Health and Safety regulations. The program emphasizes diversity in applicant teams and requires a Plan for Enhancing Diverse Perspectives, with key deadlines including submission openings starting December 28, 2024, and a close date of January 28, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NEI Collaborative Clinical Vision Research: Chair's Grant (UG1-Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Eye Institute (NEI), has announced a Notice of Funding Opportunity (NOFO) for the NEI Collaborative Clinical Vision Research: Chair's Grant (UG1), aimed at supporting large-scale clinical trials focused on vision disorders. This funding opportunity is intended for projects that evaluate interventions for screening, diagnosing, preventing, or treating vision disorders, specifically requiring a clinical trial with a clear scientific rationale and detailed study design. The NEI emphasizes the importance of these trials in advancing vision science and public health, with awards structured as cooperative agreements to ensure substantial NIH involvement in the research process. Interested applicants must submit their proposals by May 25, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)." This initiative aims to support the characterization and efficacy studies of neurotherapeutic agents intended for treating neurological disorders, with a focus on conducting pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate the biological activity of proposed therapeutic agents. The program emphasizes the importance of rigorous experimental design, collaboration, and the inclusion of diverse perspectives in research teams, aligning with NIH's mission to translate research discoveries into effective therapies. Interested applicants can apply for funding up to $499,000 per year for a total project duration not exceeding three years, with the application deadline set for October 20, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-225.html.